vs
Side-by-side financial comparison of TPG Mortgage Investment Trust, Inc. (MITT) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
TPG Mortgage Investment Trust, Inc. is the larger business by last-quarter revenue ($20.4M vs $20.4M, roughly 1.0× Sight Sciences, Inc.). TPG Mortgage Investment Trust, Inc. runs the higher net margin — 65.0% vs -20.4%, a 85.4% gap on every dollar of revenue. On growth, TPG Mortgage Investment Trust, Inc. posted the faster year-over-year revenue change (17.7% vs 6.9%). Over the past eight quarters, TPG Mortgage Investment Trust, Inc.'s revenue compounded faster (9.1% CAGR vs 2.9%).
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
MITT vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $20.4M |
| Net Profit | $13.3M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 67.1% | -18.0% |
| Net Margin | 65.0% | -20.4% |
| Revenue YoY | 17.7% | 6.9% |
| Net Profit YoY | -7.0% | 64.9% |
| EPS (diluted) | $0.27 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $20.4M | ||
| Q3 25 | $19.5M | $19.9M | ||
| Q2 25 | $17.8M | $19.6M | ||
| Q1 25 | $18.8M | $17.5M | ||
| Q4 24 | $17.4M | $19.1M | ||
| Q3 24 | $14.9M | $20.2M | ||
| Q2 24 | $16.4M | $21.4M | ||
| Q1 24 | $17.2M | $19.3M |
| Q4 25 | $13.3M | $-4.2M | ||
| Q3 25 | $20.0M | $-8.2M | ||
| Q2 25 | $3.9M | $-11.9M | ||
| Q1 25 | $11.5M | $-14.2M | ||
| Q4 24 | $14.3M | $-11.8M | ||
| Q3 24 | $16.6M | $-11.1M | ||
| Q2 24 | $3.9M | $-12.3M | ||
| Q1 24 | $20.9M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 67.1% | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | 20.9% | -59.6% | ||
| Q1 25 | 54.6% | -79.2% | ||
| Q4 24 | 76.7% | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | 18.4% | -59.2% | ||
| Q1 24 | — | -76.4% |
| Q4 25 | 65.0% | -20.4% | ||
| Q3 25 | 102.5% | -41.0% | ||
| Q2 25 | 22.2% | -61.0% | ||
| Q1 25 | 60.9% | -80.8% | ||
| Q4 24 | 82.2% | -62.1% | ||
| Q3 24 | 111.3% | -54.9% | ||
| Q2 24 | 24.0% | -57.7% | ||
| Q1 24 | 121.6% | -84.4% |
| Q4 25 | $0.27 | $-0.07 | ||
| Q3 25 | $0.47 | $-0.16 | ||
| Q2 25 | $-0.05 | $-0.23 | ||
| Q1 25 | $0.21 | $-0.28 | ||
| Q4 24 | $0.30 | $-0.23 | ||
| Q3 24 | $0.40 | $-0.22 | ||
| Q2 24 | $-0.02 | $-0.25 | ||
| Q1 24 | $0.55 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.8M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $560.7M | $63.9M |
| Total Assets | $8.7B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.8M | $92.0M | ||
| Q3 25 | $59.0M | $92.4M | ||
| Q2 25 | $88.7M | $101.5M | ||
| Q1 25 | $115.5M | $108.8M | ||
| Q4 24 | $118.7M | $120.4M | ||
| Q3 24 | $102.5M | $118.6M | ||
| Q2 24 | $120.9M | $118.2M | ||
| Q1 24 | $100.3M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $560.7M | $63.9M | ||
| Q3 25 | $559.8M | $64.3M | ||
| Q2 25 | $536.4M | $70.0M | ||
| Q1 25 | $543.9M | $77.6M | ||
| Q4 24 | $543.4M | $87.5M | ||
| Q3 24 | $540.1M | $95.0M | ||
| Q2 24 | $533.5M | $101.6M | ||
| Q1 24 | $539.6M | $109.2M |
| Q4 25 | $8.7B | $115.3M | ||
| Q3 25 | $9.0B | $116.3M | ||
| Q2 25 | $7.5B | $122.0M | ||
| Q1 25 | $7.3B | $129.7M | ||
| Q4 24 | $6.9B | $142.8M | ||
| Q3 24 | $7.0B | $143.6M | ||
| Q2 24 | $7.1B | $149.7M | ||
| Q1 24 | $6.4B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $59.6M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 4.48× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $59.6M | $-1.8M | ||
| Q3 25 | $17.4M | $-8.7M | ||
| Q2 25 | $11.5M | $-7.5M | ||
| Q1 25 | $12.0M | $-11.6M | ||
| Q4 24 | $55.8M | $-3.5M | ||
| Q3 24 | $14.5M | $362.0K | ||
| Q2 24 | $13.7M | $-9.5M | ||
| Q1 24 | $12.0M | $-9.8M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | — | $-9.5M | ||
| Q1 24 | — | $-9.9M |
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -51.4% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 4.48× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 3.50× | — | ||
| Q1 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MITT
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
